Diabetes Mellitus Clinical Trial
Official title:
Efficacy and Safety of Android Artificial Pancreas System Use at Home Among Type 1 Diabetes Mellitus Adults in China: Protocol of a 26-Week, Free-Living, Randomized, Open-Label, Two-Arm, Two-Phase, Crossover Trial
This is a 26-week randomized, free-living, open-label, two-arm, two-phase, crossover trial. Participants will receive two interventions at different phases, including the Android artificial pancreas system(AndroidAPS-rt-CGM) and sensor-augment pump(SAP), and use marketed rapid-acting insulin analogs (insulin Aspart, insulin Lispro, or insulin Glulisine) normally used in their usual clinical care. The safety and efficacy of AndroidAPS-rt-CGM and SAP in adult T1DM with suboptimal glycemic control will be compared to explore whether the use of AndroidAPS-rt-CGM in adult T1DM with suboptimal glycemic control will be associated with better glycemic control with no increased hypoglycemia.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | September 30, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Prior to this study: 1. Type 1 diabetes mellitus(T1DM) was diagnosed by an endocrinologist for at least one year. 2. Aged from 18 to 75 years. 3. HbA1c was 7.0% ~ 11%. 4. on multiple daily injection(MDI) or insulin pump therapy for =3 months with less than 20% insulin dose changes. 5. The total daily dose(TDD) were=0.3 u/kg /day, and the basal rate was =0.05 u/hour. 6. Regular self-monitoring of blood glucose (=3 times per day) for =2 months. 7. Lived with an adult willing to care for the subject during the study. 8. Women of childbearing age are willing to use appropriate contraceptive measures. 9. Willing to follow the research protocol. 10. Have daily access to a Wi-Fi network. Exclusion Criteria: Prior to this study: 1. Severe acute or chronic complications of diabetes mellitus. 2. Frequent severe hypoglycemia in the past three months. 3. Patients who have used closed-loop therapy in the last two months (excluding those who have recently used CGM) and those participating in other studies. 4. Abnormal liver function (ALT was 2.5 times higher than the upper limit of normal). 5. Moderate to severe renal impairment (eGFR<60ml/min/1.73m2). 6. Clinically significant heart disease. 7. Pregnant or planning pregnancy. 8. Used drugs that can interfere with glucose metabolism (e.g., exogenous glucocorticoids, nonselective beta-blockers, monoamine oxidase inhibitors) in the past eight weeks. 9. Frequent acetaminophen, drug abuse, and excessive drinking. 10. Known allergy to medical-grade adhesives or CGM and its affiliated components. 11. Severe visual or hearing impairment. 12. Severe skin disease at the site of sensor implantation. 13. Plan to undergo elective surgery requiring general anesthesia during the study. 14. Eating disorders such as anorexia or bulimia. 15. Other physical or psychological conditions deemed inappropriate for inclusion by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Jinhua Yan | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Third Affiliated Hospital, Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time in range(TIR) | TIR(3.9-10.0 mmol/l) derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase | |
Secondary | Glycosylated Hemoglobin A1c(HbA1c) | centralized HbA1c will be measured on the last day of each phase | on the last day of each phase | |
Secondary | Time in target range(TIT) | TIT(3.9-7.8 mmol/l) derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | Time above range(TAR) | TAR(> 10.0 mmol/L and > 13.9 mmol/L) derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | Time below range(TBR) | TBR(< 3.9 mmol/L and <3.0 mmol/L) derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | Mean blood glucose value(MBG) | MBG derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | Standard deviation(SD) | SD derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | Coefficient of variation(CV) | CV derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | Mean amplitude of glucose excursions(MAGE) | MAGE derived from CGM will be collected during the last 2 weeks of each phase. | during the last 2 weeks of each phase. | |
Secondary | the Chinese version of Hypoglycemia Fear Survey II-Worry Scale(HFS-II) | The Chinese version of Hypoglycemia Fear Survey II- Worry Scale is used to evaluate the psychological status of diabetic patients. Change in Hypoglycemia Fear Scale (HFS) score will be assessed in week 12 and week 26 adjusted for baseline(week 0 and week 14). These validated surveys include 18 questions to measure hypoglycemia-related anxiety and fear. Each item is rated on a 5-point Likert scale from 0(never related) to 4(very related). "Never relative" scores 1, " and "very related" scores 4. Patients with higher scores are considered with more anxiety and fear of hypoglycemia. The change in HFS-II will be assessed in week 12 and week 26 adjusted for baseline(weeks 0 and 14). | in week 0 ,week 12, week 14, and week 26 | |
Secondary | Frequency of hypoglycemia events | Level 1 is defined as sensor glucose =3.9mmol/L;level 2 is defined as sensor glucose =3.0mmol/L; level 3 is defined as hypoglycemia accompanied by severe cognitive impairment requiring the assistance of another individual to administer rescue therapy. | 12 weeks for each arm of the crossover | |
Secondary | Frequency of diabetic ketoacidosis (DKA) | DKA can be diagnosed when the following three points are met: 1)plasma glucose level =13.9mmol/L;2)pH<7.3 or bicarbonate <18 mmol/L;3)serum ketone =3mmol/L or urine ketone=2+. | 12 weeks for each arm of the crossover | |
Secondary | Frequency of serious adverse events about device | Serious adverse device effect(ADE) is defined as an event related to the use of the study device which is fatal or life-threatening, resulting in persistent or substantial disability, or requires (or prolonged) hospitalization. | 12 weeks for each arm of the crossover |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |